

## **Final Pre-Meeting Agenda**

# **Classical and Novel Biomarkers and Omics in CVD – Driving Toward More Medical Value**

## *Enhancing CV Therapeutic Benefit by Precision Medicine*

**Sixteenth Annual Meeting: Transatlantic Heart Failure  
Biomarker Working Group**

### **Virtual Meeting**

**October 2nd, 2021**

### **Scientific Programme**

*Chairmen:*

*Kirkwood F. Adams, Jr. (Chapel Hill, US)*

*Faiez Zannad (Nancy, FR)*



# Meeting Agenda

## Virtual Workshop

### Session 1 Prediction and Prevention of Heart Failure

Saturday, October 2, 2021

#### Progress in Omics Markers to Phenotype and Predict CHF

<b>10:05 – 10:37AM</b> (US EST)	Investigator Viewpoint Investigator Viewpoint	<i>Jasper Tromp, MD (Groningen, NL)</i> <i>Christian Delles, MD (Glasgow, UK)</i>
<b>16:05 – 16:37</b> (FR CET)	Investigator Viewpoint Investigator Viewpoint	<i>Anders Målarstig, PhD (Stockholm, SE)</i> <i>John Cleland, MD (Glasgow, UK)</i>

<b>10:37 – 11:00AM</b> (US EST)	<b>Group Discussion</b>	
<b>16:37 – 17:00</b> (FR CET)	<b>Discussion Leaders</b> Investigator Viewpoint Investigator Viewpoint	<i>Joao Ferreira MD, PhD (Nancy, FR)</i> <i>Faiez Zannad, MD, PhD (Nancy, FR)</i>

#### Systems Biology, Bio-informatics and Complex Networks in HF Research

<b>11:00 – 11:32AM</b> (US EST)	Investigator Viewpoint Investigator Viewpoint	<i>Job A.J. Verdonschot, MD, MSc (Maastricht, NL)</i> <i>David Lanfear, MD, MS (Detroit, US)</i>
<b>17:00 – 17:32</b> (FR CET)	Investigator Viewpoint Investigator Viewpoint	<i>Christopher de Filippi, MD (Baltimore, US)</i> <i>Nicolas Girerd, MD, PhD (Nancy, FR)</i>

<b>11:32AM–12:00PM</b> (US EST)	<b>Group Discussion</b>	
<b>17:32 – 18:00</b> (FR CET)	<b>Discussion Leaders</b> Investigator Viewpoint Investigator Viewpoint	<i>Jasper Tromp, MD (Groningen, NL)</i> <i>Peter Liu, MD, PhD (Hamilton, CA)</i>

<b>12:00 – 12:45PM / 18:00 – 18:45</b> (US EST)	<b>Meal Break</b> (FR CET)	
--	-------------------------------	--

# Meeting Agenda

## Virtual Workshop

### Session 2

## Biomarkers in Heart Failure: Management and Mechanisms

Saturday, October 2, 2021

### Reducing Treatment Gaps in CHF Rx - Role of Precision Medicine, Biomarkers and Other Novel Strategies - Pivotal Studies Going Forward?

<b>12:45 – 1:09PM</b> (US EST)	Investigator Viewpoint	<i>Kirkwood F. Adams, Jr., MD (Chapel Hill, US)</i>
	Investigator Viewpoint	<i>Hans-Peter Brunner-La Rocca, MD (Maastricht, NL)</i>
<b>18:45 – 19:09</b> (FR CET)	Investigator Viewpoint	<i>Javed Butler, MD (Jackson, US)</i>

<b>1:09 – 1:35PM</b> (US EST)	<b>Group Discussion</b>	
<b>19:09 – 19:35</b> (FR CET)	<b>Discussion Leaders</b>	
	Investigator Viewpoint	<i>Ileana Piña, MD, MPH (Detroit, US)</i>
	Investigator Viewpoint	<i>Martin Hülsmann, MD (Vienna, AT)</i>
	Investigator Viewpoint	<i>Stephanie Dunlap, DO (Augusta, US)</i>

### Establishing Biobanks to Elucidate/Interpret HF Clinical Trial Findings: Next Steps

<b>1:35 – 1:59PM</b> (US EST)	Investigator Viewpoint	<i>Joao Ferreira MD, PhD (Nancy, FR)</i>
	Investigator Viewpoint	<i>Faiez Zannad, MD, PhD (Nancy, FR)</i>
<b>19:35 – 19:59</b> (FR CET)	Industry Viewpoint	<i>André Ziegler, PhD (Roche Dx)</i>

<b>1:59 – 2:25PM</b> (US EST)	<b>Group Discussion</b>	
<b>19:59 – 20:25</b> (FR CET)	<b>Discussion Leaders</b>	
	Investigator Viewpoint	<i>Alexandre Mebazaa, MD (Paris, FR)</i>
	Investigator Viewpoint	<i>Roberto Latini, MD (Milan, IT)</i>

<b>2:25 – 2:35PM / 20:25 – 20:35</b> (US EST)      (FR CET)	<b>Break</b>
--	--------------

# Meeting Agenda

## Virtual Workshop

### Session 2

## Biomarkers in Heart Failure: Management and Mechanisms

Saturday, October 2, 2021

### Novel Mechanistic Insights in HFrEF and HFpEF Rx – Pathways to Biotargets and Biotherapeutics

**2:35 – 3:15PM**  
(US EST)

Investigator Viewpoint  
Investigator Viewpoint  
Investigator Viewpoint  
Investigator Viewpoint  
Investigator Viewpoint

*Thomas Thum, MD, PhD (Hanover, DE)*  
*Arantxa González, PhD (Pamplona, ES)*  
*Natalia Lopez, PhD (Pamplona, ES)*  
*Antoni Bayes-Genis, MD, PhD (Barcelona, ES)*  
*James Januzzi, Jr., MD (Boston, US)*

**20:35 – 21:15**  
(FR CET)

**3:15 – 3:45PM**  
(US EST)

#### **Group Discussion**

**21:15 – 21:45**  
(FR CET)

**Discussion Leaders**  
Investigator Viewpoint  
Investigator Viewpoint  
Industry Viewpoint

*Robert Mentz, MD (Durham, US)*  
*Javier Diez, MD, PhD (Pamplona, ES)*  
*Pieter Muntendam, MD (G3 Pharmaceuticals)*

**3:45PM (US EST) / 21:45 (FR CET)**

**Meeting Wrap-up and Adjourn**